QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies in Collaboration With AstraZeneca
January 12, 2015 at 04:51 AM EST
QIAGEN (NASDAQ: QGEN) announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating ...